FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a bispecific molecule including at least one anti-CD38 domain and at least one anti-PD-L1 domain that is capable of simultaneous binding with an antigen of CD38 and PD-L1.
EFFECT: invention is effective for the treatment of cancer selected from a group consisting of multiple myeloma, non-Hodgkin’s lymphoma (NHL), breast cancer, melanoma and lung cancer.
10 cl, 14 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2779602C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
